Still love for B-cell as PD1-Vaxx is trialed in London ( anns 06/12/23 ) and Her-Vaxx trial has moved to Taiwan. But as she hasn't mentioned it in the interview it is not on top of her priorities - as we have been told.
If we ignore B-cell and Azer-Cel in the valuation then IMU, using CG's IPO as a guide, is fairly valued. But that could quickly change to the upside if some bigger players without an OV platform experience some FOMO and want to grab one. Then current valuations could multiply in a blink of an eye. And what better place to be in that scenario than listed on the NASDAQ. Imagine OV's would become bio-techs AI equivalent.
Without charting skills I dare to say the next move is a break out of current 10.5c-11.5c channel. Which way, no idea. But I am prepared for either way.
GLTA
Media Thread, page-11904
-
- There are more pages in this discussion • 2,388 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.6¢ | $1.037M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1882949 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 399643 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |